Plerixafor blocks CXCR4 and enables tumor cells to be mobilized from protective niches like the bone marrow and hypoxic tumor regions and making them more susceptible to therapeutic agents (Cancilla et al., 2020). The gene discussed is CXCR4; the disease is neoplasm.